RU2015144149A - Протеомные маркеры илф - Google Patents
Протеомные маркеры илф Download PDFInfo
- Publication number
- RU2015144149A RU2015144149A RU2015144149A RU2015144149A RU2015144149A RU 2015144149 A RU2015144149 A RU 2015144149A RU 2015144149 A RU2015144149 A RU 2015144149A RU 2015144149 A RU2015144149 A RU 2015144149A RU 2015144149 A RU2015144149 A RU 2015144149A
- Authority
- RU
- Russia
- Prior art keywords
- fibrotic
- level
- disease
- expression
- subject
- Prior art date
Links
- 238000000034 method Methods 0.000 claims 68
- 230000003176 fibrotic effect Effects 0.000 claims 58
- 108090000623 proteins and genes Proteins 0.000 claims 45
- 102000004169 proteins and genes Human genes 0.000 claims 43
- 239000003550 marker Substances 0.000 claims 35
- 208000019693 Lung disease Diseases 0.000 claims 31
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 29
- 201000010099 disease Diseases 0.000 claims 28
- 230000002685 pulmonary effect Effects 0.000 claims 18
- 239000012472 biological sample Substances 0.000 claims 15
- 210000004072 lung Anatomy 0.000 claims 11
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 8
- 239000003814 drug Substances 0.000 claims 8
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 8
- 230000000750 progressive effect Effects 0.000 claims 8
- 239000000556 agonist Substances 0.000 claims 7
- 108091023037 Aptamer Proteins 0.000 claims 6
- 239000005557 antagonist Substances 0.000 claims 6
- 210000004369 blood Anatomy 0.000 claims 6
- 239000008280 blood Substances 0.000 claims 6
- 108020004707 nucleic acids Proteins 0.000 claims 6
- 102000039446 nucleic acids Human genes 0.000 claims 6
- 150000007523 nucleic acids Chemical class 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- 150000003384 small molecules Chemical class 0.000 claims 6
- 229940079593 drug Drugs 0.000 claims 4
- 239000000523 sample Substances 0.000 claims 4
- 229940124597 therapeutic agent Drugs 0.000 claims 4
- 239000003172 expectorant agent Substances 0.000 claims 3
- 229940066491 mucolytics Drugs 0.000 claims 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims 3
- 208000029523 Interstitial Lung disease Diseases 0.000 claims 2
- -1 antibody Proteins 0.000 claims 2
- 210000001124 body fluid Anatomy 0.000 claims 2
- 239000010839 body fluid Substances 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000002381 plasma Anatomy 0.000 claims 2
- 210000003296 saliva Anatomy 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 210000001519 tissue Anatomy 0.000 claims 2
- 210000002700 urine Anatomy 0.000 claims 2
- 102000007469 Actins Human genes 0.000 claims 1
- 108010085238 Actins Proteins 0.000 claims 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 claims 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 claims 1
- 229940076372 protein antagonist Drugs 0.000 claims 1
- 229940076155 protein modulator Drugs 0.000 claims 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361801290P | 2013-03-15 | 2013-03-15 | |
| US201361801476P | 2013-03-15 | 2013-03-15 | |
| US61/801,476 | 2013-03-15 | ||
| US61/801,290 | 2013-03-15 | ||
| US201361874947P | 2013-09-06 | 2013-09-06 | |
| US61/874,947 | 2013-09-06 | ||
| PCT/US2014/029392 WO2014144821A1 (en) | 2013-03-15 | 2014-03-14 | Proteomic ipf markers |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2015144149A true RU2015144149A (ru) | 2017-04-21 |
Family
ID=51537804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2015144149A RU2015144149A (ru) | 2013-03-15 | 2014-03-14 | Протеомные маркеры илф |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9726677B2 (enExample) |
| EP (1) | EP2972392A4 (enExample) |
| JP (1) | JP2016519763A (enExample) |
| KR (1) | KR20150130408A (enExample) |
| CN (1) | CN105122068A (enExample) |
| BR (1) | BR112015023699A2 (enExample) |
| CA (1) | CA2901384A1 (enExample) |
| HK (1) | HK1219533A1 (enExample) |
| MX (1) | MX2015012778A (enExample) |
| RU (1) | RU2015144149A (enExample) |
| WO (1) | WO2014144821A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10236078B2 (en) | 2008-11-17 | 2019-03-19 | Veracyte, Inc. | Methods for processing or analyzing a sample of thyroid tissue |
| JP6078339B2 (ja) | 2009-05-07 | 2017-02-08 | ベラサイト インコーポレイテッド | 甲状腺状態の診断のための方法および組成物 |
| CA2901384A1 (en) | 2013-03-15 | 2014-09-18 | Intermune, Inc. | Proteomic ipf markers |
| US11976329B2 (en) | 2013-03-15 | 2024-05-07 | Veracyte, Inc. | Methods and systems for detecting usual interstitial pneumonia |
| US12297505B2 (en) | 2014-07-14 | 2025-05-13 | Veracyte, Inc. | Algorithms for disease diagnostics |
| EP3770274A1 (en) | 2014-11-05 | 2021-01-27 | Veracyte, Inc. | Systems and methods of diagnosing idiopathic pulmonary fibrosis on transbronchial biopsies using machine learning and high dimensional transcriptional data |
| WO2018191747A1 (en) | 2017-04-14 | 2018-10-18 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treating pulmonary arterial hypertension |
| WO2018191751A1 (en) * | 2017-04-14 | 2018-10-18 | Arizona Board Of Regents On Behalf Of The University Of Arizonia | Compositions and methods for treating pulmonary fibrosis |
| CN107677835B (zh) * | 2017-09-26 | 2019-08-09 | 上海市肺科医院 | 一种ae-ipf的蛋白标记物及其应用 |
| EP3837550A1 (en) * | 2018-08-17 | 2021-06-23 | Roche Diagnostics GmbH | Circulating bmp10 (bone morphogenic protein 10) in the assessment of atrial fibrillation |
| WO2020090683A1 (ja) * | 2018-10-29 | 2020-05-07 | 国立大学法人東京医科歯科大学 | 間質性肺炎患者の呼吸機能の低下リスクに関する情報を取得する方法及びその利用 |
| JP7300642B2 (ja) * | 2019-06-14 | 2023-06-30 | 国立大学法人浜松医科大学 | 特発性肺線維症の予後予測方法 |
| CN110333358A (zh) * | 2019-06-24 | 2019-10-15 | 浙江大学 | 一种急性肺损伤小鼠肺脏全免疫细胞特征图谱的建立方法 |
| JP7614477B2 (ja) * | 2019-08-02 | 2025-01-16 | 国立医薬品食品衛生研究所長 | 間質性肺炎のタンパク質診断バイオマーカー |
| WO2021181368A1 (en) * | 2020-03-13 | 2021-09-16 | Puretech Lyt 100, Inc. | Methods of treating respiratory disease with deupirfenidone |
| US20230146286A1 (en) * | 2020-04-17 | 2023-05-11 | Japan As Represented By Director General Of National Institute Of Health Sciences | Protein diagnostic biomarker for severe drug eruption |
| CN113607955A (zh) * | 2020-09-16 | 2021-11-05 | 广州中医药大学顺德医院(佛山市顺德区中医院) | 新型冠状病毒肺炎分期与疗效评估细胞因子标志物及其应用 |
| CN113533750A (zh) * | 2020-10-22 | 2021-10-22 | 广州中医药大学顺德医院(佛山市顺德区中医院) | 一种区分新型冠状病毒肺炎患者与健康者的系统 |
| KR20230036541A (ko) * | 2021-09-07 | 2023-03-14 | 주식회사 에프엔씨티바이오텍 | 폐섬유화증의 바이오마커 및 치료 표적으로서 csf3r |
| WO2023081299A1 (en) * | 2021-11-05 | 2023-05-11 | Spiritus Therapeutics, Inc. | A purified enriched population exosomes derived from individuals with a chronic progressive lung disease for noninvasive detection, staging, and medical monitoring of disease progression |
| CN114563562A (zh) * | 2022-03-01 | 2022-05-31 | 复旦大学附属中山医院 | Prdx6联合铁离子检测在ards进程监测中的应用 |
| KR20240026005A (ko) * | 2022-08-19 | 2024-02-27 | 울산대학교 산학협력단 | 특발성 폐섬유증 환자의 진단 및 경과예측용 호기 바이오마커 |
| CN119947728A (zh) * | 2022-09-28 | 2025-05-06 | 勃林格殷格翰国际有限公司 | 生物标志物在用pde4b抑制剂治疗纤维化病症中的用途 |
| CN117025745B (zh) * | 2022-11-18 | 2024-02-23 | 中国医学科学院北京协和医院 | 分子标志物在诊断干燥综合征中的应用 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5235033A (en) | 1985-03-15 | 1993-08-10 | Anti-Gene Development Group | Alpha-morpholino ribonucleoside derivatives and polymers thereof |
| US5034506A (en) | 1985-03-15 | 1991-07-23 | Anti-Gene Development Group | Uncharged morpholino-based polymers having achiral intersubunit linkages |
| US5496938A (en) | 1990-06-11 | 1996-03-05 | Nexstar Pharmaceuticals, Inc. | Nucleic acid ligands to HIV-RT and HIV-1 rev |
| US5637459A (en) | 1990-06-11 | 1997-06-10 | Nexstar Pharmaceuticals, Inc. | Systematic evolution of ligands by exponential enrichment: chimeric selex |
| US5582981A (en) | 1991-08-14 | 1996-12-10 | Gilead Sciences, Inc. | Method for identifying an oligonucleotide aptamer specific for a target |
| US6019988A (en) * | 1996-11-18 | 2000-02-01 | Bristol-Myers Squibb Company | Methods and compositions for enhancing skin permeation of drugs using permeation enhancers, when drugs and/or permeation enhancers are unstable in combination during long-term storage |
| US7091323B2 (en) * | 2001-04-24 | 2006-08-15 | Bayer Corporation | Human TIMP-1 antibodies |
| AUPR638101A0 (en) * | 2001-07-13 | 2001-08-09 | Bioa Pty Limited | Composition and method for treatment of disease |
| JP2003238592A (ja) * | 2001-12-13 | 2003-08-27 | Japan Tobacco Inc | 組織及び血管の再生のための医薬及びその方法 |
| CN101745112A (zh) * | 2002-07-19 | 2010-06-23 | 艾博特生物技术有限公司 | TNFα相关疾病的治疗 |
| US7888485B2 (en) * | 2003-03-26 | 2011-02-15 | Georgetown University | Anti-pleiotrophin antibodies and methods of use thereof |
| US20060211752A1 (en) * | 2004-03-16 | 2006-09-21 | Kohn Leonard D | Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpression |
| ES2303925T3 (es) * | 2004-08-12 | 2008-09-01 | F. Hoffmann-La Roche Ag | Metodo para diagnosticar la fibrosis hepatica. |
| US7704503B2 (en) * | 2005-02-14 | 2010-04-27 | Wyeth Llc | Use of IL-17F in diagnosis and therapy of airway inflammation |
| EP1757940A1 (en) * | 2005-08-26 | 2007-02-28 | Cézanne S.A.S. | In vitro method for diagnosing and monitoring renal cell carcinoma (RCC) using MMP-7 as humoral biomarker for RCC |
| US20110129845A1 (en) * | 2007-01-29 | 2011-06-02 | Crc For Asthma And Airways Ltd. | Method of diagnosis |
| US8709731B2 (en) * | 2007-08-24 | 2014-04-29 | Oncotherapy Science, Inc. | DKK1 oncogene as therapeutic target for cancer and a diagnosing marker |
| WO2010028274A1 (en) * | 2008-09-05 | 2010-03-11 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Marker panels for idiopathic pulmonary fibrosis diagnosis and evaluation |
| US8568996B2 (en) * | 2008-10-21 | 2013-10-29 | University of Pittsburgh—of the Commonwealth System of Higher Education | MMP activation peptide detection in biological samples |
| WO2010083392A2 (en) * | 2009-01-16 | 2010-07-22 | The Ohio State University Research Foundation | Ets-2 biomarkers for fibrotic diseases and uses thereof |
| WO2010102167A1 (en) * | 2009-03-05 | 2010-09-10 | Becton, Dickinson And Company | Matrix metalloproteinase-7 (mmp-7) monoclonal antibodies and methods for their use in the detection of ovarian cancer |
| MX2011009810A (es) * | 2009-03-27 | 2011-09-30 | Zymogenetics Inc | Composiciones y metodos para usar proteinas de union multiespecificas que comprenden una combinacion anticuerporeceptor. |
| BR112012008080A2 (pt) * | 2009-08-21 | 2017-07-04 | Gilead Biologics Inc | ensaios de rastreamento in vivo. |
| CN102640001A (zh) * | 2009-11-05 | 2012-08-15 | 诺瓦提斯公司 | 预测纤维化进展的生物标记物 |
| US8637232B2 (en) * | 2010-01-21 | 2014-01-28 | The Regents Of The University Of Michigan | Biomarkers for lung disease monitoring |
| KR20140064971A (ko) * | 2011-09-19 | 2014-05-28 | 제넨테크, 인크. | c-met 길항제 및 B-raf 길항제를 포함하는 조합 치료 |
| CA2901384A1 (en) | 2013-03-15 | 2014-09-18 | Intermune, Inc. | Proteomic ipf markers |
-
2014
- 2014-03-14 CA CA2901384A patent/CA2901384A1/en not_active Abandoned
- 2014-03-14 KR KR1020157027988A patent/KR20150130408A/ko not_active Withdrawn
- 2014-03-14 WO PCT/US2014/029392 patent/WO2014144821A1/en not_active Ceased
- 2014-03-14 US US14/213,970 patent/US9726677B2/en active Active - Reinstated
- 2014-03-14 BR BR112015023699A patent/BR112015023699A2/pt not_active IP Right Cessation
- 2014-03-14 EP EP14762377.1A patent/EP2972392A4/en not_active Withdrawn
- 2014-03-14 HK HK16107519.9A patent/HK1219533A1/zh unknown
- 2014-03-14 CN CN201480021359.5A patent/CN105122068A/zh active Pending
- 2014-03-14 RU RU2015144149A patent/RU2015144149A/ru unknown
- 2014-03-14 JP JP2016503081A patent/JP2016519763A/ja active Pending
- 2014-03-14 MX MX2015012778A patent/MX2015012778A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN105122068A (zh) | 2015-12-02 |
| EP2972392A1 (en) | 2016-01-20 |
| CA2901384A1 (en) | 2014-09-18 |
| MX2015012778A (es) | 2016-01-20 |
| BR112015023699A2 (pt) | 2017-07-18 |
| JP2016519763A (ja) | 2016-07-07 |
| EP2972392A4 (en) | 2017-03-22 |
| WO2014144821A1 (en) | 2014-09-18 |
| HK1219533A1 (zh) | 2017-04-07 |
| KR20150130408A (ko) | 2015-11-23 |
| US9726677B2 (en) | 2017-08-08 |
| US20140286929A1 (en) | 2014-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2015144149A (ru) | Протеомные маркеры илф | |
| JP2016519763A5 (enExample) | ||
| Staudacher et al. | Use of endotypes, phenotypes, and inflammatory markers to guide treatment decisions in chronic rhinosinusitis | |
| Myles et al. | Importance of intraoperative oliguria during major abdominal surgery: findings of the restrictive versus liberal fluid therapy in major abdominal surgery trial | |
| Arron et al. | Noninvasive biomarkers that predict treatment benefit from biologic therapies in asthma | |
| Xaubet et al. | Guidelines for the diagnosis and treatment of idiopathic pulmonary fibrosis | |
| McCombe et al. | Serial measurements of phosphorylated neurofilament-heavy in the serum of subjects with amyotrophic lateral sclerosis | |
| JP6755241B2 (ja) | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法 | |
| JP6755240B2 (ja) | 新規分子バイオマーカーを使用して慢性閉塞性肺疾患（ｃｏｐｄ）を診断する方法 | |
| MX2018003376A (es) | Prediccion de la respuesta clinica a antagonistas de il23 mediante el uso de biomarcadores de la via de il23. | |
| JP2017510622A (ja) | 筋萎縮を予測するバイオマーカー、方法および使用 | |
| EP2503338A3 (en) | CD73 as a biomarker for monitoring development of diseases and assessing the efficacy of therapies | |
| US20160178584A1 (en) | Methods for diagnosing and assessing kidney disease | |
| JPWO2018008764A1 (ja) | 軽度認知障害又はアルツハイマー型認知症の評価方法 | |
| JP2008536480A5 (enExample) | ||
| RU2014145259A (ru) | Прогнозирование нежелательных явлений у пациентов с предполагаемым диагнозом хронической сердечной недостаточности | |
| JP2015500988A (ja) | 肺障害のバイオマーカーとしてのｌｔｂｐ２ | |
| JP2024023615A (ja) | 感染性疾患の症状を有する患者において入院を必要とする病状のリスクを予測するためのｐｒｏ－ａｄｍ | |
| RU2016147122A (ru) | Применение серелаксина для снижения gdf-15 | |
| JP2018504909A5 (enExample) | ||
| US8309299B2 (en) | Combination therapy and method for assessing resistance to treatment | |
| RU2019144031A (ru) | Способ диагностики или мониторинга функции почек или диагностики дисфункции почек | |
| JP2023521156A (ja) | 重症急性呼吸器症候群（ｓａｒｓ）における疾患進行を予後診断するためのプロアドレノメデュリン | |
| CN102300875A (zh) | 肾病相关的生物标记 | |
| WO2010005077A1 (ja) | パーキンソン病の疾患関連たんぱく質およびその使用 |